1. Home
  2. GKOS vs TMHC Comparison

GKOS vs TMHC Comparison

Compare GKOS & TMHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$107.89

Market Cap

5.4B

Sector

Health Care

ML Signal

HOLD

Logo Taylor Morrison Home Corporation

TMHC

Taylor Morrison Home Corporation

HOLD

Current Price

$64.50

Market Cap

6.2B

ML Signal

HOLD

Company Overview

Basic Information
Metric
GKOS
TMHC
Founded
1998
1936
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Homebuilding
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
6.2B
IPO Year
2015
2013

Fundamental Metrics

Financial Performance
Metric
GKOS
TMHC
Price
$107.89
$64.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
6
Target Price
$122.08
$76.83
AVG Volume (30 Days)
1.1M
881.3K
Earning Date
10-29-2025
10-22-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
10.21
EPS
N/A
8.31
Revenue
$469,820,000.00
$8,378,329,000.00
Revenue This Year
$30.89
N/A
Revenue Next Year
$24.36
N/A
P/E Ratio
N/A
$7.75
Revenue Growth
30.38
6.98
52 Week Low
$73.16
$51.90
52 Week High
$163.71
$74.09

Technical Indicators

Market Signals
Indicator
GKOS
TMHC
Relative Strength Index (RSI) 73.56 64.08
Support Level $104.11 $61.79
Resistance Level $107.18 $63.98
Average True Range (ATR) 4.40 1.75
MACD 1.26 0.70
Stochastic Oscillator 92.97 94.37

Price Performance

Historical Comparison
GKOS
TMHC

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About TMHC Taylor Morrison Home Corporation

Taylor Morrison Home Corp is an American residential construction company engaged in residential homebuilding and the development of lifestyle communities. It designs, builds, and sells single and multi-family detached and attached homes in traditionally high growth markets for entry level, move-up, and resort lifestyle buyers. The company has four reportable segments: East, Central, West, and Financial Services. The majority of the company's revenue is derived from its West Segment.

Share on Social Networks: